Patents by Inventor Rajeev S. Bhide

Rajeev S. Bhide has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazinone compounds and their use to treat diseases
    Patent number: 7030118
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof useful for inducing mitotic arrest thereby making them useful as anti-cancer agents and other diseases which can be treated by inducing mitotic arrest.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: April 18, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Louis J. Lombardo, Rajeev S. Bhide, Kyoung S. Kim, Songfeng Lu
  • Pyrrolotriazine inhibitors of kinases
    Patent number: 6982265
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: January 3, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
  • Azaindole kinase inhibitors
    Patent number: 6969717
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: November 29, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Rejean Ruel, Carl Thibault, Alexandre L'Heureux
  • Pyrrolotriazine kinase inhibitors
    Patent number: 6951859
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: October 4, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Robert M. Borzilleri
  • Process for preparing certain pyrrolotriazine compounds
    Patent number: 6933386
    Abstract: The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: August 23, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Rajeev S. Bhide, Junying Fan, Luca Parlanti, Stephanie Barbosa, Ligang Qian, Zhen-Wei Cai, Francis S. Gibson
  • Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases
    Patent number: 6869952
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: March 22, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa
  • Inhibitors of farnesyl protein transferase
    Publication number: 20040181068
    Abstract: The present invention discloses the identification of the novel inhibitors of farnesyl protein transferase and ras protein farnesylation. The compounds and pharmaceutical compositions disclosed herein are useful in treating diseases associated with farnesyl protein transferase, such as cancer.
    Type: Application
    Filed: February 10, 2004
    Publication date: September 16, 2004
    Inventor: Rajeev S. Bhide
  • Heterocyclic inhibitors of kinases
    Publication number: 20040077696
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: June 18, 2003
    Publication date: April 22, 2004
    Inventors: Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
  • Process for preparing certain pyrrolotriazine compounds
    Publication number: 20040077858
    Abstract: The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula 1
    Type: Application
    Filed: July 18, 2003
    Publication date: April 22, 2004
    Inventors: Rajeev S. Bhide, Junying Fan, Luca Parlanti, Stephanie Barbosa, Ligang Qian, Zhen-Wei Cai, Francis S. Gibson
  • Novel inhibitors of kinases
    Publication number: 20040072832
    Abstract: The present invention provides compounds of formula I, 1
    Type: Application
    Filed: July 18, 2003
    Publication date: April 15, 2004
    Inventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa
  • Pyrrolotriazine kinase inhibitors
    Publication number: 20040063708
    Abstract: The present invention provides compounds of formula I, 1
    Type: Application
    Filed: August 4, 2003
    Publication date: April 1, 2004
    Inventors: Rajeev S. Bhide, Robert M. Borzilleri
  • Azaindole kinase inhibitors
    Publication number: 20040063707
    Abstract: The present invention provides compounds of formula I, 1
    Type: Application
    Filed: July 18, 2003
    Publication date: April 1, 2004
    Inventors: Rajeev S. Bhide, Rejean Ruel, Carl Thibault, Alexandre L'Heureux
  • Pyrrolotriazinone compounds and their use to teat diseases
    Publication number: 20030232832
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: May 20, 2003
    Publication date: December 18, 2003
    Inventors: Louis J. Lombardo, Rajeev S. Bhide, Kyoung S. Kim, Songfeng Lu
  • Inhibitors of farnesyl protein transferase
    Patent number: 6602883
    Abstract: Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: August 5, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Charles Z. Ding, John T. Hunt, Soong-Hoon Kim, Katerina Leftheris
  • Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
    Patent number: 6458783
    Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: October 1, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Charles Z. Ding, John T. Hunt, Katerina Leftheris, Rajeev S. Bhide
  • Inhibitors of farnesyl protein transferase
    Patent number: 6387926
    Abstract: Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: May 14, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Charles Z. Ding, John T. Hunt, Soong-Hoon Kim, Katerina Leftheris